Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Eli Lilly and	Pfizer	Novo Nordisk A/S	Abbott Laboratories	Novartis
Symbol	NYSE:LLY	NYSE:PFE	NYSE:NVO	NYSE:ABT	NYSE:NVS
Price Information
Current Price	$232.18	$44.19	$102.10	$125.30	$83.57
50-Day Moving Average	$251.32	$45.29	$98.50	$123.93	$90.45
52-Week Low	$129.21	$33.36	$63.22	$100.34	$77.04
52-Week High	$275.87	$51.86	$107.24	$129.70	$98.52
MarketRank™
Overall Score	2.7	2.7	1.4	2.9	2.2
Analysis Score	2.5	2.1	0.0	2.4	3.1
Community Score	4.8	4.8	4.0	4.8	4.3
Dividend Score	2.5	3.3	1.7	4.2	2.5
Ownership Score	2.5	2.5	0.0	2.5	0.0
Earnings & Valuation Score	1.3	0.6	1.3	0.6	1.3
Analyst Ratings
Consensus Recommendation	Buy	Hold	Hold	Buy	Hold
Consensus Price Target	$250.81	$43.33	N/A	$129.42	$108.50
% Upside from Price Target	8.03% upside	-1.94% downside	N/A	3.29% upside	29.83% upside
Trade Information
Market Cap	$222.67 billion	$247.76 billion	$240.43 billion	$222.13 billion	$186.92 billion
Beta	0.25	0.74	0.41	0.66	0.54
Average Volume	3,512,151	30,833,553	988,739	5,384,768	1,887,725
Sales & Book Value
Annual Revenue	$24.54 billion	$41.91 billion	$19.45 billion	$34.61 billion	$48.66 billion
Price / Sales	9.07	5.91	12.36	6.42	3.84
Cashflow	$8.68 per share	$3.01 per share	$3.20 per share	$5.42 per share	$8.24 per share
Price / Cash	26.76	14.66	31.95	23.11	10.14
Book Value	$6.09 per share	$11.42 per share	$4.12 per share	$18.62 per share	$24.76 per share
Price / Book	38.12	3.87	24.78	6.73	3.38
Profitability
Net Income	$6.19 billion	$9.62 billion	$6.46 billion	$4.50 billion	$8.07 billion
EPS	$7.93	$2.22	$2.76	$3.65	$5.75
Trailing P/E Ratio	34.81	18.97	33.37	35.30	21.16
Forward P/E Ratio	27.35	12.96	28.92	26.89	12.49
P/E Growth	1.86	1.58	2.81	2.45	2.07
Net Margins	22.71%	23.06%	34.17%	15.85%	17.83%
Return on Equity (ROE)	119.12%	26.49%	72.72%	26.75%	25.25%
Return on Assets (ROA)	15.81%	10.73%	30.72%	12.31%	10.74%
Dividend
Annual Payout	$3.40	$1.56	$0.77	$1.80	$2.08
Dividend Yield	1.46%	3.53%	0.75%	1.44%	2.49%
Three-Year Dividend Growth	42.31%	-10.94%	13.65%	35.85%	13.60%
Payout Ratio	42.88%	70.27%	27.90%	49.32%	36.17%
Years of Consecutive Dividend Growth	1 Years	1 Years	N/A	49 Years	1 Years
Debt
Debt-to-Equity Ratio	2.21%	0.50%	0.19%	0.52%	0.46%
Current Ratio	1.15%	1.37%	1.06%	1.79%	0.80%
Quick Ratio	0.89%	1.12%	0.80%	1.36%	0.56%
Ownership Information
Institutional Ownership Percentage	81.65%	64.93%	5.58%	72.05%	9.90%
Insider Ownership Percentage	0.13%	0.05%	0.07%	1.50%	0.01%
Miscellaneous
Employees	35,000	78,500	45,323	109,000	105,794
Shares Outstanding	959.03 million	5.61 billion	2.35 billion	1.77 billion	2.24 billion
Next Earnings Date	10/26/2021 (Confirmed)	10/26/2021 (Estimated)	10/29/2021 (Estimated)	10/20/2021 (Estimated)	10/26/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	Ex-Novartis Exec Joins Immunology-Focused Biotech Inspired By Keytruda's Side Effects - Scrip scrip.pharmaintelligence.informa.com - September 23 at 7:29 PM
	HHS lines up Novartis, Lilly, AstraZeneca and 3 other drugmakers for fines due to drug discount violations - Endpoints News endpts.com - September 23 at 2:29 PM
	Novartis expands gene therapy pipeline with Arctos Medical takeover - PharmaTimes pharmatimes.com - September 23 at 9:29 AM
	Novartis Acquires Arctos Medical, Expanding Optogenetics Profile - Pharmaceutical Technology Magazine pharmtech.com - September 23 at 12:12 AM
	Novartis Acquires Arctos Medical, Expanding Optogenetics Profile - BioPharm International biopharminternational.com - September 22 at 7:08 PM
	Novartis acquires Arctos Medical to develop gene therapy programme - European Pharmaceutical Review europeanpharmaceuticalreview.com - September 22 at 2:08 PM
	Novartis reshuffling doesn't portend a pullback from gene therapy, company says - FiercePharma fiercepharma.com - September 22 at 2:08 PM
	Novartis snaps up another ophthalmic gene therapy company - The Pharma Letter thepharmaletter.com - September 22 at 9:07 AM
	The Zacks Analyst Blog Highlights: Facebook, Walmart, Novartis, PayPal and Advanced Micro Devices finance.yahoo.com - September 22 at 9:07 AM
	Top Research Reports for Facebook, Walmart & Novartis - Entrepreneur entrepreneur.com - September 22 at 12:37 AM
	Former Novartis Exec Joins MiroBio to Fight Autoimmune Disease - BioSpace biospace.com - September 21 at 7:35 PM
	Top Research Reports for Facebook, Walmart & Novartis - Nasdaq nasdaq.com - September 21 at 7:35 PM
	So what happened with Novartis' gene therapy group? Here's your answer - Endpoints News endpts.com - September 21 at 7:35 PM
	Novartis Adds to Optogenetics Portfolio with Arctos Medical Buy - BioSpace biospace.com - September 21 at 7:35 PM
	Top Research Reports for Facebook, Walmart & Novartis finance.yahoo.com - September 21 at 7:35 PM
	Is Novartis AG (NVS) a Stock to Watch After Losing -2.49% This Week? - InvestorsObserver investorsobserver.com - September 21 at 2:34 PM
	Global Antibiotics Market Size, Analysis, and Top Vendors 2027 – Novartis AG, Bayer AG, Janssen Pharmaceuticals, Astellas Pharma, Inc., Pfizer, Inc. and others – Stillwater Current - Stillwater Current stillwatercurrent.com - September 21 at 9:33 AM
	Novartis Buys Gene Therapy Firm Arctos Medical in Vision Loss Treatment Push - U.S News & World Report Money money.usnews.com - September 21 at 9:33 AM
	Novartis veteran Barth takes the helm at autoimmune biotech MiroBio - FierceBiotech fiercebiotech.com - September 21 at 9:33 AM
	Diving deeper into inherited retinal disorders, Novartis gobbles up another bite-sized optogenetics biotech - Endpoints News endpts.com - September 21 at 4:11 AM
	Novartis buys gene therapy firm Arctos Medical in vision loss treatment push - Reuters reuters.com - September 21 at 4:11 AM
	European Stock Futures Higher; Fed Meeting Looms Large finance.yahoo.com - September 21 at 4:11 AM
	Novartis buys gene therapy firm Arctos Medical in vision loss treatment push finance.yahoo.com - September 21 at 4:11 AM
	Keywords Studios picks Novartis executive Bertrand Bodson as new boss - The Times thetimes.co.uk - September 20 at 11:11 PM
	As Bayer, Novartis stack up their radiopharmaceutical data at #ESMO21, a key debate takes shape - Endpoints News endpts.com - September 20 at 6:10 PM
	Novartis (NYSE:NVS) Downgraded by Deutsche Bank Aktiengesellschaft to Sell marketbeat.com - September 20 at 7:53 AM

Date	Company	Brokerage	Action
9/20/2021	Pfizer	SVB Leerink	Boost Price Target
9/20/2021	Novartis	Deutsche Bank Aktiengesellschaft	Downgrade
9/14/2021	Pfizer	SVB Leerink	Reiterated Rating
9/13/2021	Pfizer	JPMorgan Chase & Co.	Boost Price Target
9/3/2021	Novo Nordisk A/S	Berenberg Bank	Reiterated Rating
8/31/2021	Abbott Laboratories	BTIG Research	Boost Price Target
8/30/2021	Eli Lilly and	Cowen	Boost Price Target
8/23/2021	Novo Nordisk A/S	Credit Suisse Group	Reiterated Rating
8/23/2021	Novo Nordisk A/S	Citigroup	Reiterated Rating
8/23/2021	Abbott Laboratories	Cowen	Boost Price Target
8/17/2021	Novo Nordisk A/S	UBS Group	Reiterated Rating
8/11/2021	Novo Nordisk A/S	Morgan Stanley	Reiterated Rating
8/9/2021	Eli Lilly and	Argus	Boost Price Target
8/6/2021	Novo Nordisk A/S	JPMorgan Chase & Co.	Reiterated Rating
8/5/2021	Eli Lilly and	DZ Bank	Upgrade
8/5/2021	Novo Nordisk A/S	Barclays	Reiterated Rating
8/5/2021	Novo Nordisk A/S	Bank of America	Upgrade
8/5/2021	Novo Nordisk A/S	DNB Markets	Upgrade
8/4/2021	Eli Lilly and	JPMorgan Chase & Co.	Boost Price Target
8/4/2021	Eli Lilly and	Morgan Stanley	Boost Price Target
8/4/2021	Eli Lilly and	Mizuho	Boost Price Target
8/3/2021	Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft	Reiterated Rating
7/30/2021	Pfizer	Mizuho	Boost Price Target
7/29/2021	Pfizer	The Goldman Sachs Group	Set Price Target
7/29/2021	Pfizer	Morgan Stanley	Boost Price Target
7/29/2021	Pfizer	Royal Bank of Canada	Set Price Target
7/29/2021	Pfizer	SVB Leerink	Boost Price Target
7/28/2021	Novartis	JPMorgan Chase & Co.	Reiterated Rating
7/27/2021	Eli Lilly and	Truist	Initiated Coverage
7/27/2021	Pfizer	Truist	Initiated Coverage
7/23/2021	Abbott Laboratories	Morgan Stanley	Boost Price Target
7/23/2021	Abbott Laboratories	Credit Suisse Group	Boost Price Target
7/23/2021	Abbott Laboratories	Raymond James	Boost Price Target
7/22/2021	Novartis	Deutsche Bank Aktiengesellschaft	Downgrade
7/20/2021	Abbott Laboratories	SVB Leerink	Boost Price Target
7/19/2021	Novo Nordisk A/S	Barclays	Reiterated Rating
7/15/2021	Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft	Reiterated Rating
7/12/2021	Abbott Laboratories	Wells Fargo & Company	Boost Price Target
7/7/2021	Eli Lilly and	Mizuho	Reiterated Rating
7/6/2021	Eli Lilly and	Barclays	Boost Price Target
7/2/2021	Eli Lilly and	Truist Securities	Boost Price Target
7/2/2021	Eli Lilly and	Truist	Boost Price Target
6/24/2021	Eli Lilly and	Cantor Fitzgerald	Boost Price Target
6/24/2021	Eli Lilly and	Cowen	Boost Price Target
6/17/2021	Pfizer	Royal Bank of Canada	Boost Price Target
6/15/2021	Eli Lilly and	JPMorgan Chase & Co.	Boost Price Target
6/15/2021	Pfizer	Berenberg Bank	Reiterated Rating
6/14/2021	Eli Lilly and	The Goldman Sachs Group	Boost Price Target
6/8/2021	Eli Lilly and	Truist Securities	Reiterated Rating
6/8/2021	Eli Lilly and	Truist Financial	Reiterated Rating
6/2/2021	Abbott Laboratories	BTIG Research	Lower Price Target
6/2/2021	Abbott Laboratories	Credit Suisse Group	Lower Price Target
6/2/2021	Abbott Laboratories	Barclays	Lower Price Target
6/2/2021	Abbott Laboratories	Wells Fargo & Company	Lower Price Target
6/2/2021	Abbott Laboratories	Raymond James	Lower Price Target
6/2/2021	Abbott Laboratories	Morgan Stanley	Lower Price Target
6/2/2021	Abbott Laboratories	Citigroup	Reiterated Rating
5/24/2021	Pfizer	JPMorgan Chase & Co.	Set Price Target
5/24/2021	Pfizer	The Goldman Sachs Group	Set Price Target
5/24/2021	Abbott Laboratories	Barclays	Initiated Coverage
5/13/2021	Pfizer	The Goldman Sachs Group	Reiterated Rating
5/12/2021	Pfizer	Mizuho	Reiterated Rating
5/11/2021	Novartis	Morgan Stanley	Reiterated Rating
5/10/2021	Pfizer	Morgan Stanley	Boost Price Target
5/6/2021	Pfizer	Mizuho	Downgrade
5/5/2021	Pfizer	SVB Leerink	Boost Price Target
5/5/2021	Pfizer	JPMorgan Chase & Co.	Boost Price Target
5/5/2021	Pfizer	Barclays	Boost Price Target
4/28/2021	Eli Lilly and	Morgan Stanley	Lower Price Target
4/28/2021	Eli Lilly and	Mizuho	Lower Price Target
4/28/2021	Eli Lilly and	Barclays	Lower Price Target
4/28/2021	Novartis	JPMorgan Chase & Co.	Reiterated Rating
4/28/2021	Novartis	Oddo Bhf	Upgrade
4/21/2021	Abbott Laboratories	Morgan Stanley	Boost Price Target
4/20/2021	Abbott Laboratories	William Blair	Reiterated Rating
4/19/2021	Novartis	UBS Group	Reiterated Rating
4/15/2021	Abbott Laboratories	Atlantic Securities	Initiated Coverage
4/7/2021	Pfizer	Royal Bank of Canada	Initiated Coverage
4/6/2021	Pfizer	The Goldman Sachs Group	Set Price Target
3/31/2021	Pfizer	The Goldman Sachs Group	Set Price Target
3/26/2021	Pfizer	SVB Leerink	Lower Price Target
3/23/2021	Pfizer	Berenberg Bank	Reiterated Rating
3/23/2021	Novartis	Societe Generale	Reiterated Rating
3/22/2021	Novartis	Sanford C. Bernstein	Initiated Coverage
3/16/2021	Novartis	Argus	Reiterated Rating
3/15/2021	Eli Lilly and	Truist Securities	Boost Price Target
3/11/2021	Abbott Laboratories	Raymond James	Boost Price Target
3/10/2021	Novartis	Argus	Downgrade
2/12/2021	Eli Lilly and	Cowen	Boost Price Target
2/11/2021	Novo Nordisk A/S	UBS Group	Reiterated Rating
2/4/2021	Eli Lilly and	Morgan Stanley	Boost Price Target
2/4/2021	Novo Nordisk A/S	Barclays	Reiterated Rating
2/2/2021	Novartis	Morgan Stanley	Reiterated Rating
2/1/2021	Eli Lilly and	Truist	Boost Price Target
2/1/2021	Eli Lilly and	Mizuho	Boost Price Target
2/1/2021	Novartis	Cowen	Downgrade
1/28/2021	Abbott Laboratories	Wells Fargo & Company	Boost Price Target
1/28/2021	Abbott Laboratories	Cowen	Boost Price Target
1/28/2021	Abbott Laboratories	Credit Suisse Group	Boost Price Target
1/28/2021	Abbott Laboratories	Morgan Stanley	Boost Price Target
1/28/2021	Abbott Laboratories	SVB Leerink	Boost Price Target
1/28/2021	Abbott Laboratories	Raymond James	Boost Price Target
1/22/2021	Novartis	Barclays	Reiterated Rating
1/20/2021	Novo Nordisk A/S	Credit Suisse Group	Downgrade
1/15/2021	Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft	Initiated Coverage
1/15/2021	Novartis	Deutsche Bank Aktiengesellschaft	Initiated Coverage
1/8/2021	Novartis	Morgan Stanley	Reiterated Rating
12/3/2020	Novartis	Argus	Boost Price Target
11/25/2020	Novartis	UBS Group	Reiterated Rating
11/12/2020	Novo Nordisk A/S	JPMorgan Chase & Co.	Reiterated Rating
11/10/2020	Novartis	JPMorgan Chase & Co.	Reiterated Rating
11/6/2020	Novo Nordisk A/S	Morgan Stanley	Downgrade
11/3/2020	Novo Nordisk A/S	Societe Generale	Reiterated Rating
10/15/2020	Novo Nordisk A/S	Morgan Stanley	Reiterated Rating
9/29/2020	Novo Nordisk A/S	Berenberg Bank	Initiated Coverage
9/29/2020	Novartis	Berenberg Bank	Initiated Coverage
9/23/2020	Novartis	Oddo Bhf	Downgrade
9/10/2020	Novartis	UBS Group	Upgrade
9/1/2020	Novartis	Morgan Stanley	Upgrade
8/18/2020	Novo Nordisk A/S	UBS Group	Reiterated Rating
8/12/2020	Novartis	JPMorgan Chase & Co.	Reiterated Rating
8/3/2020	Novo Nordisk A/S	Morgan Stanley	Reiterated Rating
7/28/2020	Novartis	Morgan Stanley	Reiterated Rating
7/6/2020	Novo Nordisk A/S	Bank of America	Downgrade
5/18/2020	Novo Nordisk A/S	Morgan Stanley	Reiterated Rating

(Data available from 9/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources